emaglutide is a GLP-1 analog that:

• Stimulates insulin secretion.
• Reduces glucagon secretion.
• Delays gastric emptying.
• Reduces appetite and caloric intake.

WEGOVY is a GLP-1 receptor agonist indicated for:

Reducing cardiovascular events in adults with cardiovascular disease and obesity or overweight.

Chronic weight management in:

• • Adults and adolescents (12+) with obesity.

  • Adults with overweight and at least one weight-related comorbidity.

Initiation & Titration Schedule:

• Weeks 1–4: 0.25 mg
• Weeks 5–8: 0.5 mg
• Weeks 9–12: 1 mg
• Weeks 13–16: 1.7 mg
• Week 17 onward: 2.4 mg (recommended maintenance dose)

Common (≥5%):

• GI issues: nausea, vomiting, diarrhea, constipation, abdominal pain.
• Others: headache, fatigue, dizziness, hypoglycemia (in T2DM), dyspepsia.

Serious:

• Acute pancreatitis, gallbladder disease, kidney injury, suicidal ideation, allergic reactions.

• History of MTC or MEN 2.

• Prior serious hypersensitivity to semaglutide or formulation ingredients.

Includes risks of:

• Thyroid tumors
• Acute pancreatitis
• Gallbladder disease (e.g., cholelithiasis, cholecystitis)
• Hypoglycemia (especially with insulin or sulfonylureas)
• Kidney injury (especially with severe GI symptoms or pre-existing impairment)
• Severe GI events
• Hypersensitivity reactions (e.g., anaphylaxis)
• Diabetic retinopathy complications
• Increased heart rate
• Suicidal ideation
• Pulmonary aspiration during anesthesia